Precipio (PRPO) Q4 2025 earnings summary

Executive summary

• Focused on improving cancer diagnostics through integrated clinical laboratory services and proprietary product development, targeting hematologic malignancies.

• Operates two divisions: pathology services (diagnostic testing) and products (proprietary assay kits), both supporting innovation and revenue.

• Achieved a 30% increase in diagnostic cases processed year-over-year, driving revenue growth.

• Maintains a single operating segment with a unique R&D model leveraging clinical operations for product development.

Financial highlights

• Net sales for 2025 were $24.0 million, up 30% from $18.5 million in 2024, driven by higher diagnostic service volumes.

• Gross profit increased to $10.7 million (45% margin) from $7.6 million (41% margin) year-over-year.

• Operating loss narrowed to $1.2 million from $4.2 million in the prior year.

• Net loss was $0.4 million, a significant improvement from $4.3 million in 2024.

• Cash increased to $2.7 million at year-end, with positive operating cash flow of $0.7 million.

• Working capital improved to $2.3 million from a deficit of $0.8 million.

Outlook and guidance

• Management expresses substantial doubt about the ability to continue as a going concern over the next twelve months without additional revenue growth or financing.

• Plans to continue expanding proprietary product commercialization and maintain pathology service operations.

• Ongoing focus on operational efficiency, regulatory compliance, and cost management.